| Literature DB >> 29976628 |
Ulrich H Weidle1, Fabian Birzele2, Georg Tiefenthaler3.
Abstract
In this review we summarize the principles of anti-metastatic therapy with selected serpin family proteins, such as pigment epithelial-derived factor (PEDF) and maspin, as well as inter α-trypsin inhibitor (IαIs) light chains (bikunin) and heavy chains (ITIHs). Case-by-case, antimetastatic activity may be dependent or independent of the protease-inhibitory activity of the corresponding proteins. We discuss the incidence of target deregulation in different tumor entities, mechanisms of deregulation, context-dependent functional issues as well as in vitro and in vivo target validation studies with transfected tumor cells or recombinant protein as anti-metastatic agents. Finally, we comment on possible clinical evaluation of these proteins in adjuvant therapy. CopyrightEntities:
Keywords: Adjuvant anti-metastatic therapy; bikunin; in vitro and in vivo target validation; inter α-trypsin inhibitors; maspin; pigment-epithelial derived factor; protein substitution therapy; review
Mesh:
Substances:
Year: 2018 PMID: 29976628 PMCID: PMC6070713 DOI: 10.21873/cgp.20081
Source DB: PubMed Journal: Cancer Genomics Proteomics ISSN: 1109-6535 Impact factor: 4.069